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Serous Retinal Detachment Following Combined Photodynamic 
Therapy and Intravitreal Bevacizumab Injection
Eui Yon Kim, MD, Jong Wan Kim, MD, Jun Bum Kim, MD, Ho Min Lew, MD
Department of Ophthalmology, Ajou University School of Medicine, Suwon, Korea
We report a case of serous retinal detachment following combined photodynamic therapy (PDT) and intravitreal 
bevacizumab injection in subfoveal choroidal neovascularization (CNV).
A 53-year-old woman was diagnosed with subfoveal CNV secondary to age-related macular degeneration 
(AMD) and treated with combined PDT and intravitreal bevacizumab injection. One day after treatment, the patient 
experienced a sudden decline of vision and optical coherence tomography (OCT) showed serous retinal detach-
ment involving the macula. She was managed conservatively with an oral steroid beginning on the second day of 
the combined treatment and the subretinal fluid started to decrease one week following the initiation of steroids.
This case suggests that combined PDT and intravitreal injection of bevacizumab can be associated with serous 
retinal detachment. Additional studies are needed to establish the safety and complications following this 
treatment regimen.
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Fig. 1. (A) Fundoscopic photography and fluorescein angiography 
showing leakage of fluorescein dye consistent with subfoveal 
choroidal neovascularization (CNV) before combined photodynamic 
therapy (PDT) and intravtreal bevacizumab injection. (B) Leakage 
of fluorescein dye decreased two weeks after the combined PDT 
and intravtreal bevacizumab injection.
Intravitreal bevacizumab injection and photodynamic therapy 
(PDT) with Verteporfin are effective for the treatment of 
choroidal neovascularization (CNV).
1,2 Recently, combined 
PDT with Verteporfin and intravitreal bevacizumab injection 
has shown a synergistic effect and might reduce the need for 
retreatment and cyclic injections of bevacizumab.
3
Single treatments of PDT and intravitral bevacizumab 
injection are considered relatively safe and effective.
4,5 How-
ever, PDT may cause visual disturbances, subretinal hemorrhage, 
suprachoroidal hemorrhage and retinal pigment epithelial 
tear, and there are reported complications following intravitreal 
bevacizumab injection such as retinal pigment epithelial tear 
and acute glaucoma.
6-11
Chung et al.
12 reported a case of retinal detachment with 
macular hole following combined PDT and intravitreal 
bevacizumab injection but the safety of combined treatment 
with these two modalitiesis not well established.
We herein present a case of serous retinal detachment after 
combined PDT and intravtreal bevacizumab injection in 
subfoveal CNV.
Case Report
A 53-year-old woman presented with metamorphopsia in 
her right eye. She was diagnosed with subfoveal CNV secon-
dary to age-related macular degeneration (AMD) and the 
best-corrected visual acuity of the right eye was 20/50. PDT 
with Verteporfin was performed according to the standard 
protocol of the Treatment of Age-Related Macular Degenera-EY Kim, et al. SEROUS RETINAL DETACHMENT AFTER AVASTIN
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Fig. 2. Optical coherence tomography (OCT) before and after the 
combined photodynamic therapy (PDT) and intravtreal bevacizumab 
injection. (A) Before combined PDT and intravtreal bevacizumab 
injection, OCT image demonstrates a minimally hyporeflective 
area in the subneuroretinal space. (B) One day after the combined 
treatment, OCT image reveals significant enlargement of the hypo-
reflective area, representing the amount of fluid accumulation. 
(C) One week after taking the oral steroid, the subretinal fluid has 
absorbed nearly completely, similar to pretreatment OCT findings.
tion with Photodynamic Therapy Investigation and repeated 
after 5 months.
13 The visual acuity of the involved eye did not 
change.
Fifteen months after the second PDT, fluorescein angio-
graphy of the affected eye revealed persistent subfoveal 
CNV and the best corrected visual acuity remained 20/50 
(Fig. 1A, 2A). Combined PDT according to the same standard 
protocol and 1.25 mg intravitreal bevacizumab injection was 
performed on the same day. One day after the treatment, the 
patient’s vision had decreased to counting fingers. Fundus 
examination and optical coherence tomography (OCT) showed 
serous retinal detachment involving the macula (Fig. 2B).
On post-treatmentday two, the patient was initiated on an 
oral steroid (Triamcinolone
Ⓡ 24 mg #1) to complete a two 
week course. One week into steroid therapy, the visual acuity 
remained the same, but OCT findings of the right eye showed 
decreased serous retinal detachment (Fig. 2C). The vision 
slightly improved to 20/200 upon completion of the two week 
steroid course and fluorescein angiography showed decreased 
leakage of fluorescein dye (Fig. 1B).
Discussion
There have been several reports about serous retinal 
detachment after PDT treatment.
7,9,14 Mennel et al.
7 quantified 
transient serous retinal detachment in CNV after PDT using 
OCT. Kim et al.
9 also suggested that serous retinal detach-
ment might develop following PDT but might also resolve 
spontaneously several days following treatment. However, 
there is neither a published report of serous retinal detachment 
after the combined use of PDT and intravitreal bevacizumab 
injection nor following intravitreal bevacizumab injection alone.
Several mechanisms may be responsible for subretinal 
fluid accumulation after combined treatment with PDT and 
intravitreal bevacizumab injection. The PDT may induce 
fluid leakage from the CNV itself or damage of retinal pigment 
epithelium causing an alteration of the blood-retinal barrier.
7,9 
Bevacizumab may cause instability of the intraretinal and sub-
retinal fluid and subsequent serous retinal detachment by rapidly 
modulating the permeability and activity of the CNV.
10,12
In our patient, there was no evidence of increased sub-
retinal fluid after the first two treatments of PDT alone and 
the PDT protocol was the same for all three treatments. 
Occurrence of the serous retinal detachment just after combined 
PDT and intravitreal bevacizumab injection suggests the 
interaction of these two modalities as a possible causal role. 
However, the definitive causation of serous retinal detachment 
in PDT alone, intravitreal bevacizumab injection alone or 
combined treatment cannot be determined.
A two week course of oral steroids was used to manage the 
serous retinal detachment after the combined treatment of 
PDT and intravitreal bevacizumab injection. The acute infla-
mmatory reaction following either modality may be relieved 
by systemic steroids. Kim et al.
9 injected Triamcinolone
Ⓡ 
into the vitreous in a patient with serous retinal detachment 
following PDT, whereas, we elected to use a more conservative 
management with an oral steroid.
In conclusion, combined PDT and intravitreal bevacizumab 
injection can be associated with serous retinal detachment 
which may cause sudden visual loss. Additional studies are 
needed to establish the standard protocol, safety and compli-
cations regarding the combined treatment of PDT and intra-
vitreal bevacizumab injection.
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